Search
Results: 784
Cell Cycle Regulation in Macrophages and Susceptibility to HIV-1.
Macrophages are the first line of defence against invading pathogens. They play a crucial role in immunity but also in regeneration and homeostasis. Their remarkable plasticity in their phenotypes and function provides them with...
HIV SAMHD1 cell arrest Cell Cycle macrophage Animals Cell Cycle Cell Cycle Checkpoints Cells Cultured DNA Damage G1 Phase Gram-Negative Bacteria HIV-1 Histone Deacetylase Inhibitors Humans MACROPHAGES Phosphorylation Resting Phase Cell Cycle SAM Domain and HD Domain-Containing Protein 1 vif Gene Products Human Immunodeficiency Virus vpr Gene Products Human Immunodeficiency Virus
First international workshop of the ATM and cancer risk group (4-5 December 2019).
Fabienne Lesueur, Douglas F Easton, Anne-Laure Renault, Sean V Tavtigian, Jonine L Bernstein, Zsofia Kote-Jarai, Rosalind A Eeles, Dijana Plaseska-Karanfia, Lidia Feliubadaló, Spanish ATM working group, Banu Arun, Natalie Herold, Beatrix Versmold, Rita Katharina Schmutzler, GC-HBOC, Tú Nguyen-Dumont, Melissa C Southey, Leila Dorling, Alison M Dunning, Paola Ghiorzo, Bruna Samia Dalmasso, Eve Cavaciuti, Dorothée Le Gal, Nicholas J Roberts, Mev Dominguez-Valentin, Matti Rookus, Alexander MR Taylor, Alisa M Goldstein, David E Goldgar, CARRIERS and Ambry Groups, Dominique Stoppa-Lyonnet, Nadine Andrieu
Apr 14, 2021
The first International Workshop of the ATM and Cancer Risk group focusing on the role of Ataxia-Telangiectasia Mutated (ATM) gene in cancer was held on December 4 and 5, 2019 at Institut Curie in Paris, France. It was motivated...
ATM, ATR, and DNA-PK
In vertebrate cells, the DNA damage response is controlled by three related kinases: ATM, ATR, and DNA-PK. It has been 20 years since the cloning of ATR, the last of the three to be identified. During this time, our...
Animals Antineoplastic Agents Ataxia Telangiectasia Mutated Proteins Calcium-Binding Proteins Cell Nucleus DNA Damage DNA Repair Enzyme Activation History 20th Century History 21st Century Humans Models Molecular Neoplasms Phosphorylation Protein Conformation Protein Kinase Inhibitors Signal Transduction Structure-Activity Relationship Tumor Suppressor Protein p53
Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants.
Elena Bueno-Martínez, Lara Sanoguera-Miralles, Alberto Valenzuela-Palomo, Ada Esteban-Sánchez, Víctor Lorca, Inés Llinares-Burguet, Jamie Allen, Alicia García-Álvarez, Pedro Pérez-Segura, Mercedes Durán, Douglas F Easton, Peter Devilee, Maaike PG Vreeswijk, Miguel de la Hoya, Eladio A Velasco-Sampedro
Jul 15, 2022
The ataxia telangiectasia-mutated (ATM) protein is a major coordinator of the DNA damage response pathway. ATM loss-of-function variants are associated with 2-fold increased breast cancer risk. We aimed at identifying and...
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T. Durant, Elaine B. Cadogan, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Oct 27, 2020
Abstract: Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR...
Independent service operators in ATM markets
Tobias Wenzel
Feb 01, 2014
This paper studies the impact of entry of non-banks (termed Independent Service Operators, ISOs) into ATM markets. We compare two different regimes by which the ISO may generate income: (1) The ISO receives interchange fees...
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T. Durant, Elaine B. Cadogan, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Feb 09, 2021
Abstract: Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR...
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T. Durant, Elaine B. Cadogan, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Aug 03, 2021
Abstract: Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR...
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.
Gabriel Balmus, Domenic Pilger, Julia Coates, Mukerrem Demir, Matylda Sczaniecka-Clift, Ana C Barros, Michael Woods, Beiyuan Fu, Fengtang Yang, Elisabeth Chen, Matthias Ostermaier, Tatjana Stankovic, Hannes Ponstingl, Mareike Herzog, Kosuke Yusa, Francisco Munoz Martinez, Stephen T Durant, Yaron Galanty, Petra Beli, David J Adams, Allan Bradley, Emmanouil Metzakopian, Josep V Forment, Stephen P Jackson
Jan 17, 2019
Mutations in the ATM tumor suppressor gene confer hypersensitivity to DNA-damaging chemotherapeutic agents. To explore genetic resistance mechanisms, we performed genome-wide CRISPR-Cas9 screens in cells treated with the DNA...
Animals Antineoplastic Agents Ataxia Telangiectasia Mutated Proteins BRCA1 Protein CRISPR-Cas Systems Cell Line Tumor Cell Survival DNA Breaks Double-Stranded DNA End-Joining Repair DNA Ligase ATP DNA Replication Drug Resistance Neoplasm Female Humans Mice Mice Inbred NOD Mice Knockout Mouse embryonic stem cells Mutation Neoplasms Experimental Phthalazines Piperazines Topotecan
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd, Paul W. G. Wijnhoven, Antonio Ramos-Montoya, Zena Wilson, Giuditta Illuzzi, Katarzyna Falenta, Gemma N. Jones, Neil James, Christophe D. Chabbert, Jonathan Stott, Emma Dean, Alan Lau, Lucy A. Young
Jun 18, 2020
Abstract: The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA...
Independent service operators in ATM markets
Tobias Wenzel
Feb 01, 2014
This paper studies the impact of entry of non-banks (termed Independent Service Operators, ISOs) into ATM markets. We compare two different regimes by which the ISO may generate income: (1) The ISO receives interchange fees...
Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
Anne-Laure Renault, James G Dowty, Jason A Steen, Shuai Li, Ingrid M Winship, Graham G Giles, John L Hopper, Melissa C Southey, Tú Nguyen-Dumont
May 09, 2022
BACKGROUND: Multigene panel tests for breast cancer predisposition routinely include ATM as it is now a well-established breast cancer predisposition gene. METHODS: We included ATM in a multigene panel test applied to the...
Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
Anne-Laure Renault, James G Dowty, Jason A Steen, Shuai Li, Ingrid M Winship, Graham G Giles, John L Hopper, Melissa C Southey, Tú Nguyen-Dumont
Apr 01, 2022
BACKGROUND: Multigene panel tests for breast cancer predisposition routinely include ATM as it is now a well-established breast cancer predisposition gene. METHODS: We included ATM in a multigene panel test applied to the...
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Rebecca L Lloyd, Paul WG Wijnhoven, Antonio Ramos-Montoya, Zena Wilson, Giuditta Illuzzi, Katarzyna Falenta, Gemma N Jones, Neil James, Christophe D Chabbert, Jonathan Stott, Emma Dean, Alan Lau, Lucy A Young
May 23, 2021
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at...
Cell Cycle Regulation in Macrophages and Susceptibility to HIV-1
Macrophages are the first line of defence against invading pathogens. They play a crucial role in immunity but also in regeneration and homeostasis. Their remarkable plasticity in their phenotypes and function provides them with...
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Isabella ATM Ferreira, Steven A Kemp, Rawlings Datir, Akatsuki Saito, Bo Meng, Partha Rakshit, Akifumi Takaori-Kondo, Yusuke Kosugi, Keiya Uriu, Izumi Kimura, Kotaro Shirakawa, Adam Abdullahi, Anurag Agarwal, Seiya Ozono, Kenzo Tokunaga, Kei Sato, Ravindra K Gupta, Indian SARS-CoV-2 Genomics Consortium CITIID-NIHR BioResource COVID-19 Collaboration, Genotype to Phenotype Japan (G2P-Japan) Consortium
Jul 29, 2021
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of...
B.1.617 covid-19 Indian variant SARS-CoV-2 Antibody Escape evasion FITNESS infectivity neutralizing antibodies resistance spike mutation Angiotensin-Converting Enzyme 2 Animals Antibodies Neutralizing Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines Chlorocebus aethiops HEK293 Cells Humans Immune Evasion india Mutation Protein Binding SARS-CoV-2 Serine Endopeptidases Spike Glycoprotein Coronavirus Vero Cells
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.
Bo Meng, Steven A Kemp, Guido Papa, Rawlings Datir, Isabella ATM Ferreira, Sara Marelli, William T Harvey, Spyros Lytras, Ahmed Mohamed, Giulia Gallo, Nazia Thakur, Dami A Collier, Petra Mlcochova, COVID-19 Genomics UK (COG-UK) Consortium, Lidia M Duncan, Alessandro M Carabelli, Julia C Kenyon, Andrew M Lever, Anna de Marco, Christian Saliba, Katja Culap, Elisabetta Cameroni, Nicholas J Matheson, Luca Piccoli, Davide Corti, Leo C James, David L Robertson, Dalan Bailey, Ravindra K Gupta
Jul 29, 2021
Alpha Variant B.1.1.7 covid-19 SARS-CoV-2 Antibody Escape deletion infectivity neutralizing antibodies resistance spike mutation Animals Antibodies Neutralizing Antibodies Viral covid-19 Cell Line Chlorocebus aethiops HEK293 Cells Humans Immune Evasion Mutation Pandemics Phylogeny Protein Binding Recurrence SARS-CoV-2 Spike Glycoprotein Coronavirus Vero Cells
In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment
RC Ferreira, DB Rainbow, A Rubio García, ML Pekalski, L Porter, JJ Oliveira, F Waldron-Lynch, LS Wicker, JA Todd
Jul 04, 2017
We provide in this paper a detailed characterization of the human peripheral CD4$^+$ CD127$^{low}$CD25$^+$ regulatory T cell (Treg) compartment, with a particular emphasis in defining the population expressing higher levels of...
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.
Dami A Collier, Isabella ATM Ferreira, Prasanti Kotagiri, Rawlings P Datir, Eleanor Y Lim, Emma Touizer, Bo Meng, Adam Abdullahi, CITIID-NIHR BioResource COVID-19 Collaboration, Anne Elmer, Nathalie Kingston, Barbara Graves, Emma Le Gresley, Daniela Caputo, Laura Bergamaschi, Kenneth GC Smith, John R Bradley, Lourdes Ceron-Gutierrez, Paulina Cortes-Acevedo, Gabriela Barcenas-Morales, Michelle A Linterman, Laura E McCoy, Chris Davis, Emma Thomson, Paul A Lyons, Eoin McKinney, Rainer Doffinger, Mark Wills, Ravindra K Gupta
Sep 10, 2021
Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age1. Here we...
Adult Aged Aged 80 and over aging Antibodies Neutralizing Antibodies Viral Autoantibodies B-Lymphocytes BNT162 Vaccine COVID-19 Vaccines Female Health Personnel Humans Immunity Immunization Secondary Immunoglobulin A Immunoglobulin Class Switching Immunoglobulin G Immunologic Memory Inflammation Interferon-gamma Interleukin-2 Male Middle Aged SARS-CoV-2 Somatic Hypermutation Immunoglobulin Spike Glycoprotein Coronavirus T-Lymphocytes Vaccination vaccines Synthetic
Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Rebecca L Lloyd, Vaclav Urban, Francisco Muñoz-Martínez, Iñigo Ayestaran, John C Thomas, Christelle de Renty, Mark J O'Connor, Josep V Forment, Yaron Galanty, Stephen P Jackson
Oct 04, 2021
The protein kinase ATR plays pivotal roles in DNA repair, cell cycle checkpoint engagement and DNA replication. Consequently, ATR inhibitors (ATRi) are in clinical development for the treatment of cancers, including tumours...
The Innerworkings of Digital Storytelling
Traditionally, storytelling was used for entertainment and the transfer of know-how. The advent of digital media gave rise to new possibilities for telling stories. When the context is, for example, to relay information about...
Published by: IGI Global Scientific Publishing
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Petra Mlcochova, Steven A Kemp, Mahesh Shanker Dhar, Guido Papa, Bo Meng, Isabella ATM Ferreira, Rawlings Datir, Dami A Collier, Anna Albecka, Sujeet Singh, Rajesh Pandey, Jonathan Brown, Jie Zhou, Niluka Goonawardane, Swapnil Mishra, Charles Whittaker, Thomas Mellan, Robin Marwal, Meena Datta, Shantanu Sengupta, Kalaiarasan Ponnusamy, Venkatraman Srinivasan Radhakrishnan, Adam Abdullahi, Oscar Charles, Partha Chattopadhyay, Priti Devi, Daniela Caputo, Tom Peacock, Chand Wattal, Neeraj Goel, Ambrish Satwik, Raju Vaishya, Meenakshi Agarwal, Indian SARS-CoV-2 Genomics Consortium (INSACOG), Genotype to Phenotype Japan (G2P-Japan) Consortium, CITIID-NIHR BioResource COVID-19 Collaboration, Antranik Mavousian, Joo Hyeon Lee, Jessica Bassi, Chiara Silacci-Fegni, Christian Saliba, Dora Pinto, Takashi Irie, Isao Yoshida, William L Hamilton, Kei Sato, Samir Bhatt, Seth Flaxman, Leo C James, Davide Corti, Luca Piccoli, Wendy S Barclay, Partha Rakshit, Anurag Agrawal, Ravindra K Gupta
Sep 10, 2021
The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages...
Division of Inclusion and Community Engagement Newsletter, Vol. 1 No. 3, April 2023
DICE Staff
Jan 01, 0001
Pride Week recap Interfaith Iftaar Reverend Charles Rice Memorial Scholars More than skin deep: A special "Conversations About and Across Difference" Brothers of Excellence luncheon Latin Night Cloake House: Community of...
inclusion Community engagement Ursinus College Newsletter Gender and Sexuality Alliance Muslim Students Association ALMA Olivia Negro Isabella Villegas Civic and Community Engagement Higher Education
Published by: Ursinus College
Breast cancer risks associated with missense variants in breast cancer susceptibility genes.
Leila Dorling, Sara Carvalho, Jamie Allen, Michael T Parsons, Cristina Fortuno, Anna González-Neira, Stephan M Heijl, Muriel A Adank, Thomas U Ahearn, Irene L Andrulis, Päivi Auvinen, Heiko Becher, Matthias W Beckmann, Sabine Behrens, Marina Bermisheva, Natalia V Bogdanova, Stig E Bojesen, Manjeet K Bolla, Michael Bremer, Ignacio Briceno, Nicola J Camp, Archie Campbell, Jose E Castelao, Jenny Chang-Claude, Stephen J Chanock, Georgia Chenevix-Trench, NBCS Collaborators, J Margriet Collée, Kamila Czene, Joe Dennis, Thilo Dörk, Mikael Eriksson, D Gareth Evans, Peter A Fasching, Jonine Figueroa, Henrik Flyger, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat García-Closas, Graham G Giles, Gord Glendon, Pascal Guénel, Melanie Gündert, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Elaine F Harkness, Mikael Hartman, Frans BL Hogervorst, Antoinette Hollestelle, Reiner Hoppe, Anthony Howell, kConFab Investigators, SGBCC Investigators, Anna Jakubowska, Audrey Jung, Elza Khusnutdinova, Sung-Won Kim, Yon-Dschun Ko, Vessela N Kristensen, Inge MM Lakeman, Jingmei Li, Annika Lindblom, Maria A Loizidou, Artitaya Lophatananon, Jan Lubiński, Craig Luccarini, Michael J Madsen, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Dimitrios Mavroudis, Roger L Milne, Nur Aishah Mohd Taib, Kenneth Muir, Heli Nevanlinna, William G Newman, Jan C Oosterwijk, Sue K Park, Paolo Peterlongo, Paolo Radice, Emmanouil Saloustros, Elinor J Sawyer, Rita K Schmutzler, Mitul Shah, Xueling Sim, Melissa C Southey, Harald Surowy, Maija Suvanto, Ian Tomlinson, Diana Torres, Thérèse Truong, Christi J van Asperen, Regina Waltes, Qin Wang, Xiaohong R Yang, Paul DP Pharoah, Marjanka K Schmidt, Javier Benitez, Bas Vroling, Alison M Dunning, Soo Hwang Teo, Anders Kvist, Miguel de la Hoya, Peter Devilee, Amanda B Spurdle, Maaike PG Vreeswijk, Douglas F Easton
Jun 29, 2022
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain. METHODS: We analyzed data...
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.
Adam Abdullahi, David Oladele, Michael Owusu, Steven A Kemp, James Ayorinde, Abideen Salako, Douglas Fink, Fehintola Ige, Isabella ATM Ferreira, Bo Meng, Augustina Angelina Sylverken, Chika Onwuamah, Kwame Ofori Boadu, Kazeem Osuolale, James Opoku Frimpong, Rufai Abubakar, Azuka Okuruawe, Haruna Wisso Abdullahi, Gideon Liboro, Lawrence Duah Agyemang, Nana Kwame Ayisi-Boateng, Oluwatosin Odubela, Gregory Ohihoin, Oliver Ezechi, Japhet Senyo Kamasah, Emmanuel Ameyaw, Joshua Arthur, Derrick Boakye Kyei, Dorcas Ohui Owusu, Olagoke Usman, Sunday Mogaji, Adedamola Dada, George Agyei, Soraya Ebrahimi, Lourdes Ceron Gutierrez, Sani H Aliyu, Rainer Doffinger, Rosemary Audu, Richard Adegbola, Petra Mlcochova, Richard Odame Phillips, Babatunde Lawal Solako, Ravindra K Gupta
Oct 17, 2022
Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior...
|
|< |
< |
1 |